MKI67 and neoplasm: At the human level, using pre- and post-treatment paired tumor tissue, adagrasib was found capable of regulating several pathway gene signatures, particularly upregulation of inflammation and immune-related genes along with decreased Ki67 as well as increased PD-L1 expression and CD8+ tumor infiltrating T cells [54, 55].